

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Erik Buntinx  
Appl. No. : 10/580,962  
Filed : May 31, 2006  
For : USE OF D4 AND 5-HT2A ANTAGONISTS, INVERSE  
AGONISTS OR PARTIAL AGONISTS  
Art Unit : 1627  
Examiner : Sarah Pihonak  
Customer No. : 1912  
Confirmation No. : 8917

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Supplemental Information Disclosure Statement (SIDS) is being filed to supplement the Information Disclosure Statement filed on August 12, 2010 in connection with the subject application.

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant would like to direct the Examiner's attention to the references that are listed on the attached form PTO/SB/08A (4 pages). Copies of the non-patent literature documents are attached hereto.

EFS

Applicant : Erik Buntinx  
Serial No. : 10/580,962  
Filed : May 31, 2006

Page 2 of 2

Applicant is submitting the subject Supplemental Information Disclosure Statement pursuant to 37 C.F.R. §1.97(b)(4) before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114. Accordingly, no fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required in connection with this submission or to maintain the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicant  
90 Park Avenue  
New York, New York 10016  
(212) 336-8000

Dated: September 28, 2010  
New York, New York

By: /Alan D. Miller/  
Alan D. Miller  
Registration No. 42,889